The U.S. Securities and Exchange Commission (SEC) is signaling support for streamlined “minimum effective dose” disclosure rules and tightly scoped equity‑tokenizationThe U.S. Securities and Exchange Commission (SEC) is signaling support for streamlined “minimum effective dose” disclosure rules and tightly scoped equity‑tokenization

SEC chair backs “minimum effective dose” disclosure and targeted tokenization pilots

2026/03/12 23:48
3 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

The U.S. Securities and Exchange Commission (SEC) is signaling support for streamlined “minimum effective dose” disclosure rules and tightly scoped equity‑tokenization pilots via an innovation exemption, according to new remarks from Chair Paul S. Atkins.

Summary
  • Atkins calls for materiality‑focused, scaled disclosure and extending the JOBS Act “IPO on‑ramp” so smaller issuers face lighter reporting as they enter public markets.
  • He attacks “comply or explain” governance mandates as “shaming regulation,” arguing board structures and ESG metrics should be set by shareholders, not backdoor pressure.
  • On tokenization, he backs an “innovation exemption” that would cap volumes and scope but allow limited trading of tokenized securities to inform a longer‑term rule framework.

The U.S. Securities and Exchange Commission (SEC) is signaling support for streamlined disclosure rules and controlled experiments with equity tokenization, according to a new speech by Chair Paul S. Atkins at the agency’s Investor Advisory Committee meeting.​

SEC chair pushes “minimum effective dose” regulation

Atkins focused first on cutting what he called unnecessary disclosure burdens, arguing for a “minimum effective dose” approach to regulation that keeps rules tightly centered on material information and adapts requirements to company size. He also proposed extending the JOBS Act “IPO on‑ramp” regime, giving small and mid-size firms a longer glide path with scaled reporting so that more issuers are willing to go public.​

Atkins sharply criticized the SEC’s use of “comply or explain” disclosure mandates in corporate governance, branding them a form of “shaming regulation” that effectively forces companies into preferred governance models by public pressure rather than law. In his view, decisions on board structure, ESG metrics, and related governance questions should remain in the hands of shareholders and directors, not be indirectly dictated through disclosure threats.

Green light for targeted tokenization exemptions

On tokenization, Atkins took a more openly experimental stance, arguing that turning equity securities into digital tokens can improve settlement efficiency, reduce settlement risk, and strip out unnecessary intermediaries. He revealed that the SEC is considering an “innovative exemption mechanism” to allow limited trading of specific tokenized securities, using tightly scoped pilots to build experience for a long-term regulatory framework.​

That approach would effectively let tokenized equity projects move forward under controlled conditions, rather than waiting for a full top‑down rule overhaul. For crypto markets, the message is clear: the SEC is not ready to rewrite securities law for tokenization, but it is prepared to grant targeted exemptions that could bring regulated, on‑chain equity settlement closer to reality.

Market Opportunity
Union Logo
Union Price(U)
$0.0008494
$0.0008494$0.0008494
+1.49%
USD
Union (U) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.
Tags: